Department of Error (DOI:10.1016/S0140-6736(08)60834-X);Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study

The Lancet

Volumn 371, Issue 9628, 2008, Pages 1921-1926

  Douma, Stella ^a   Petidis, Konstantinos ^a   Doumas, Michael ^a   Papaefthimiou, Panagiota ^a   Triantafyllou, Areti ^a   Kartali, Niki ^a   Papadopoulos, Nikolaos ^a   Vogiatzis, Konstantinos ^a   Zamboulis, Chrysanthos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUDROCORTISONE; POTASSIUM; PRAZOSIN; SODIUM CHLORIDE; SPIRONOLACTONE; TERAZOSIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT ASSESSMENT; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 44649150565     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61868-1     Document Type: Erratum

References (37)

1. Conn J. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 (1955) 3-17
2. Kaplan N. Is there an unrecognized epidemic of primary aldosteronism? (Con). Hypertension 50 (2007) 454-458
3. Calhoun D. Is there an unrecognized epidemic of primary aldosteronism? (Pro). Hypertension 50 (2007) 447-453
4. Kaplan N. Hypokalemia in the hypertensive patient: with observations on the incidence of primary aldosteronism. Ann Intern Med 66 (1967) 1079-1090
5. Sinclair A., Isles C., Brown I., Cameron H., Murray G., and Robertson J. Secondary hypertension in a blood pressure clinic. Arch Intern Med 147 (1987) 1289-1293
6. Gifford Jr. R. Evaluation of the hypertensive patient with emphasis on detecting curable causes. Melbank Mem Fund Q 47 (1969) 170-186
7. Anderson G., Toftdahl D., Lund J., Strandgaard S., and Nielsen P. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Human Hypertens 2 (1988) 187-189
8. Lim P., Brennan G., Jung R., and MacDonald T. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353 (1999) 40
9. Mulatero P., Stowasser M., Loh K., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89 (2004) 1045-1050
10. Strauch B., Zelinka T., Hampf M., Bernhardt R., and Widimsky Jr. J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Human Hypertens 17 (2003) 349-352
11. Stowasser M., Gordon R., Gunasekera T., et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after "non-selective" screening of hypertensive patients. J Hypertens 21 (2003) 2149-2157
12. Schwartz G., and Turner S. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51 (2005) 386-394
13. Rossi G., Bernini G., Caliumi C., et al., for the PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48 (2006) 2293-2300
14. Weinberger M. Is primary aldosteronism a benign disorder? Old evidence reconfirmed. Am J Hypertens 19 (2006) 628
15. Stowasser M., Gordon R., Rutherford J., Nikwan N., Daunt N., and Slater G. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2 (2001) 156-169
16. Stowasser M., and Gordon R. Primary aldosteronism-careful investigation is essential and rewarding. Molecular Cellular Endocrinol 217 (2004) 33-39
17. Mulatero P., Dluhy R., Giachetti G., Boscaro M., Veglio F., and Stewart P. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 16 (2005) 114-119
18. Swales J., Bing R., and Pohl J. Treatment of refractory hypertension. Lancet 1 (1982) 894-896
19. Calhoun D., Zaman M., and Nishizaka M. Resistant hypertension. Curr Hypertens Rep 4 (2002) 221-228
20. Chobanian A., Bakris G., Black H., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. Hypertension 42 (2003) 1206-1252
21. Mancia G., de Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
22. Setaro J., and Black H. Refractory hypertension. N Engl J Med 327 (1992) 543-547
23. Mosso L., Carvajal C., Gonzalez A., et al. Primary aldosteronism and hypertensive disease. Hypertension 42 (2003) 161-165
24. Gallay B., Ahmad S., Xu L., Toivola B., and Davidson R. Screening for primary hyperaldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37 (2001) 699-705
25. Calhoun D., Nishizaka M., Zaman M., Thakkar R., and Weissman P. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
26. Eide I., Torjesen P., Drolsum A., Babovic A., and Lilledahl N. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22 (2004) 2217-2226
27. Martell N., Rodriguez-Cerrillo M., Grobee D., et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press 12 (2003) 149-154
28. Umpierrez G., Cantey P., Smiley D., et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 30 (2007) 1699-1703
29. Stowasser M., Sharman J., Leano R., et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 90 (2005) 5070-5076
30. Tanabe A., Naruse M., Naruse K., et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hyperten Res 20 (1997) 85-90
31. Strauch B., Petrak O., Wichterle D., Zelinka T., Holaj R., and Widimsky Jr. J. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 19 (2006) 909-914
32. Rossi G., Bernini G., Desideri G., et al. Renal damage in primary aldosteronism. Results of the PAPY study. Hypertension 48 (2006) 232-238
33. Sechi L., Novello M., Lapenna R., et al. Long term renal outcomes in patients with primary aldosteronism. JAMA 295 (2006) 2638-2645
34. Milliez P., Girerd X., Plouin P., Blacher J., Safar M., and Mourad J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 (2005) 1243-1248
35. Catena C., Colussi G., Nadalini E., et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168 (2008) 80-85
36. Mulatero P., Rabbia F., Milan A., et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40 (2002) 897-902
37. Young Jr. W. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 144 (2003) 2208-2213